ReproCell Stock

ReproCell Receivables

The Accounts Receivable of ReproCell (4978.T) as of Sep 4, 2026 is 463.65 M JPY. In the previous year, Accounts Receivable was 421.05 M JPY — a change of 10.12% (higher).

Receivables

463.65 MJPY

YoY

10.12%

Last updated:

Accounts Receivable of ReproCell is 2026 463.65 M JPY. Accounts Receivable of ReproCell was 2025 421.05 M JPY. It decreases by 10.12% higher compared to the previous year.

The ReproCell Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
132.46 M JPY
Jan 1, 2019
170.13 M JPY
Jan 1, 2020
153.37 M JPY
Jan 1, 2021
180.44 M JPY
Jan 1, 2022
347.91 M JPY
Jan 1, 2023
445.77 M JPY
Jan 1, 2024
421.05 M JPY
Jan 1, 2025
463.65 M JPY
The ReproCell Receivables history
YEARReceivablesYoY
463.65 MJPY+10.12%
421.05 MJPY-5.54%
445.77 MJPY+28.13%
347.91 MJPY+92.81%
180.44 MJPY+17.65%
153.37 MJPY-9.85%
170.13 MJPY+28.45%
132.46 MJPY+4.86%
126.32 MJPY-5.22%
133.28 MJPY+15.49%
115.40 MJPY+71.72%
67.20 MJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Accounts Receivable of ReproCell is 463.65 M JPY in 2026.

Accounts Receivable of ReproCell changed from 421.05 M JPY to 463.65 M JPY, representing a 10.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable ReproCell since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's ReproCell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ReproCell

All Key Metrics — ReproCell